JP2023071697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023071697A5 JP2023071697A5 JP2023018922A JP2023018922A JP2023071697A5 JP 2023071697 A5 JP2023071697 A5 JP 2023071697A5 JP 2023018922 A JP2023018922 A JP 2023018922A JP 2023018922 A JP2023018922 A JP 2023018922A JP 2023071697 A5 JP2023071697 A5 JP 2023071697A5
- Authority
- JP
- Japan
- Prior art keywords
- synthetic cannabinoid
- absorption enhancer
- acid
- synthetic
- oral formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 9
- 229930003827 cannabinoid Natural products 0.000 claims 8
- 239000003557 cannabinoid Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims 5
- 238000010521 absorption reaction Methods 0.000 claims 5
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims 5
- 229950011318 cannabidiol Drugs 0.000 claims 5
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims 5
- AAXZFUQLLRMVOG-UHFFFAOYSA-N 2-methyl-2-(4-methylpent-3-enyl)-7-propylchromen-5-ol Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCC)=CC(O)=C21 AAXZFUQLLRMVOG-UHFFFAOYSA-N 0.000 claims 4
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 claims 4
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 claims 4
- 239000003623 enhancer Substances 0.000 claims 4
- UCONUSSAWGCZMV-HZPDHXFCSA-N Delta(9)-tetrahydrocannabinolic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCCCC)C(C(O)=O)=C1O UCONUSSAWGCZMV-HZPDHXFCSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- ZROLHBHDLIHEMS-HUUCEWRRSA-N (6ar,10ar)-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-ol Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCC)=CC(O)=C3[C@@H]21 ZROLHBHDLIHEMS-HUUCEWRRSA-N 0.000 claims 2
- TWKHUZXSTKISQC-UHFFFAOYSA-N 2-(5-methyl-2-prop-1-en-2-ylphenyl)-5-pentylbenzene-1,3-diol Chemical compound OC1=CC(CCCCC)=CC(O)=C1C1=CC(C)=CC=C1C(C)=C TWKHUZXSTKISQC-UHFFFAOYSA-N 0.000 claims 2
- YJYIDZLGVYOPGU-XNTDXEJSSA-N 2-[(2e)-3,7-dimethylocta-2,6-dienyl]-5-propylbenzene-1,3-diol Chemical compound CCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-XNTDXEJSSA-N 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- KASVLYINZPAMNS-UHFFFAOYSA-N Cannabigerol monomethylether Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(OC)=C1 KASVLYINZPAMNS-UHFFFAOYSA-N 0.000 claims 2
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 claims 2
- XXGMIHXASFDFSM-UHFFFAOYSA-N Delta9-tetrahydrocannabinol Natural products CCCCCc1cc2OC(C)(C)C3CCC(=CC3c2c(O)c1O)C XXGMIHXASFDFSM-UHFFFAOYSA-N 0.000 claims 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical group [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000011575 calcium Chemical group 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 claims 2
- 150000001768 cations Chemical class 0.000 claims 2
- 229960004242 dronabinol Drugs 0.000 claims 2
- 239000011777 magnesium Chemical group 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- GECBBEABIDMGGL-RTBURBONSA-N nabilone Chemical compound C1C(=O)CC[C@H]2C(C)(C)OC3=CC(C(C)(C)CCCCCC)=CC(O)=C3[C@@H]21 GECBBEABIDMGGL-RTBURBONSA-N 0.000 claims 2
- 229960002967 nabilone Drugs 0.000 claims 2
- 239000011591 potassium Chemical group 0.000 claims 2
- 229910052700 potassium Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011734 sodium Chemical group 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- IQSYWEWTWDEVNO-ZIAGYGMSSA-N (6ar,10ar)-1-hydroxy-6,6,9-trimethyl-3-propyl-6a,7,8,10a-tetrahydrobenzo[c]chromene-2-carboxylic acid Chemical compound C([C@H]1C(C)(C)O2)CC(C)=C[C@H]1C1=C2C=C(CCC)C(C(O)=O)=C1O IQSYWEWTWDEVNO-ZIAGYGMSSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
- UVOLYTDXHDXWJU-UHFFFAOYSA-N Cannabichromene Chemical compound C1=CC(C)(CCC=C(C)C)OC2=CC(CCCCC)=CC(O)=C21 UVOLYTDXHDXWJU-UHFFFAOYSA-N 0.000 claims 1
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 claims 1
- VBGLYOIFKLUMQG-UHFFFAOYSA-N Cannabinol Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCCCC)C=C3OC(C)(C)C2=C1 VBGLYOIFKLUMQG-UHFFFAOYSA-N 0.000 claims 1
- IQSYWEWTWDEVNO-UHFFFAOYSA-N THCVA Natural products O1C(C)(C)C2CCC(C)=CC2C2=C1C=C(CCC)C(C(O)=O)=C2O IQSYWEWTWDEVNO-UHFFFAOYSA-N 0.000 claims 1
- WVOLTBSCXRRQFR-DLBZAZTESA-N cannabidiolic acid Chemical compound OC1=C(C(O)=O)C(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 WVOLTBSCXRRQFR-DLBZAZTESA-N 0.000 claims 1
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 claims 1
- SEEZIOZEUUMJME-VBKFSLOCSA-N cannabinerolic acid Chemical compound CCCCCC1=CC(O)=C(C\C=C(\C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-VBKFSLOCSA-N 0.000 claims 1
- SEEZIOZEUUMJME-UHFFFAOYSA-N cannabinerolic acid Natural products CCCCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1C(O)=O SEEZIOZEUUMJME-UHFFFAOYSA-N 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 229960003453 cannabinol Drugs 0.000 claims 1
- SVTKBAIRFMXQQF-UHFFFAOYSA-N cannabivarin Chemical compound C1=C(C)C=C2C3=C(O)C=C(CCC)C=C3OC(C)(C)C2=C1 SVTKBAIRFMXQQF-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 claims 1
- 150000002892 organic cations Chemical class 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical group C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024047771A JP2024075724A (ja) | 2017-01-03 | 2024-03-25 | 医薬化合物及び栄養補給剤 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762441908P | 2017-01-03 | 2017-01-03 | |
| US62/441,908 | 2017-01-03 | ||
| JP2019536222A JP7281815B2 (ja) | 2017-01-03 | 2018-01-03 | 医薬化合物及び栄養補給剤 |
| PCT/US2018/012261 WO2018129097A1 (en) | 2017-01-03 | 2018-01-03 | Medicinal compounds and nutritional supplements |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536222A Division JP7281815B2 (ja) | 2017-01-03 | 2018-01-03 | 医薬化合物及び栄養補給剤 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024047771A Division JP2024075724A (ja) | 2017-01-03 | 2024-03-25 | 医薬化合物及び栄養補給剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023071697A JP2023071697A (ja) | 2023-05-23 |
| JP2023071697A5 true JP2023071697A5 (https=) | 2023-07-12 |
| JP7466238B2 JP7466238B2 (ja) | 2024-04-12 |
Family
ID=62790943
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536222A Active JP7281815B2 (ja) | 2017-01-03 | 2018-01-03 | 医薬化合物及び栄養補給剤 |
| JP2023018922A Active JP7466238B2 (ja) | 2017-01-03 | 2023-02-10 | 医薬化合物及び栄養補給剤 |
| JP2024047771A Pending JP2024075724A (ja) | 2017-01-03 | 2024-03-25 | 医薬化合物及び栄養補給剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019536222A Active JP7281815B2 (ja) | 2017-01-03 | 2018-01-03 | 医薬化合物及び栄養補給剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024047771A Pending JP2024075724A (ja) | 2017-01-03 | 2024-03-25 | 医薬化合物及び栄養補給剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20190336472A1 (https=) |
| EP (1) | EP3565539A4 (https=) |
| JP (3) | JP7281815B2 (https=) |
| KR (1) | KR20190103302A (https=) |
| CN (1) | CN110121337A (https=) |
| AU (2) | AU2018206564B2 (https=) |
| BR (1) | BR112019013743A2 (https=) |
| CA (1) | CA3049226A1 (https=) |
| CL (1) | CL2019001832A1 (https=) |
| CO (1) | CO2019008176A2 (https=) |
| EA (1) | EA201991641A1 (https=) |
| IL (1) | IL267831A (https=) |
| MX (1) | MX2019007968A (https=) |
| WO (1) | WO2018129097A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11180781B2 (en) * | 2016-08-21 | 2021-11-23 | Insectergy, Llc | Biosynthetic cannabinoid production methods |
| EP3928776B1 (en) | 2016-04-22 | 2025-11-12 | Spoke Sciences, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
| EA201892396A1 (ru) | 2016-12-02 | 2019-04-30 | Ресептор Лайф Сайенсиз, Инк. | Быстродействующие растительные лекарственные соединения и биологически активные добавки |
| KR20190103302A (ko) * | 2017-01-03 | 2019-09-04 | 리셉터 홀딩스, 인크. | 의약 화합물 및 영양 보충제 |
| WO2019144221A1 (en) * | 2018-01-29 | 2019-08-01 | Solantech Inc. | Methods of treating and/or preventing bedsores using nabilone |
| KR20210116432A (ko) * | 2018-10-10 | 2021-09-27 | 틸레이, 인크. | 화학요법으로 유발된 메스꺼움 및 구토 치료를 위한 방법 및 제형 |
| AU2019385420A1 (en) * | 2018-11-19 | 2021-07-08 | Spoke Sciences, Inc. | N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions |
| US11759447B1 (en) | 2019-06-26 | 2023-09-19 | RCR BioPharma | Compound and method for treating diseases and disorders |
| EP3946262B1 (en) | 2019-08-30 | 2024-07-31 | Evie Sa | Loaded granules, their process of production and their uses |
| JP2023505351A (ja) | 2019-12-09 | 2023-02-08 | ニコベンチャーズ トレーディング リミテッド | 口腔用組成物のための薬剤 |
| US12171872B2 (en) | 2019-12-09 | 2024-12-24 | Nicoventures Trading Limited | Oral compositions and methods of manufacture |
| CN113040337B (zh) * | 2021-04-22 | 2022-12-09 | 四川大学 | 一种熏肉制品及其制备方法 |
| WO2024253228A1 (ko) * | 2023-06-09 | 2024-12-12 | 주식회사 메타파인즈 | 악액질 및 근손실의 예방 또는 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001523221A (ja) | 1996-09-01 | 2001-11-20 | ファーモス コーポレイション | 親油性物質の促進された生物学的利用能のための固形共沈物 |
| AU2002352974A1 (en) * | 2001-11-29 | 2003-06-10 | Emisphere Technologies, Inc. | Formulations for oral administration of cromolyn sodium |
| US9308175B2 (en) | 2006-09-15 | 2016-04-12 | Echo Pharmaceuticals B.V. | Dosage unit for sublingual, buccal or oral administration of water-insoluble pharmaceutically active substances |
| NZ609356A (en) | 2010-11-25 | 2014-10-31 | Aop Orphan Pharmaceuticals Ag | Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin |
| WO2013032934A1 (en) * | 2011-08-26 | 2013-03-07 | Aegis Therapeutics, Llc | Compositions and methods thereof for oral administration of drugs |
| CA2845443A1 (en) * | 2014-03-04 | 2015-09-04 | Pharmascience Inc. | Orally disintegrating tablet of nabilone and method of manufacturing |
| EP3928776B1 (en) | 2016-04-22 | 2025-11-12 | Spoke Sciences, Inc. | Fast-acting plant-based medicinal compounds and nutritional supplements |
| KR20190103302A (ko) | 2017-01-03 | 2019-09-04 | 리셉터 홀딩스, 인크. | 의약 화합물 및 영양 보충제 |
-
2018
- 2018-01-03 KR KR1020197022846A patent/KR20190103302A/ko not_active Ceased
- 2018-01-03 EA EA201991641A patent/EA201991641A1/ru unknown
- 2018-01-03 MX MX2019007968A patent/MX2019007968A/es unknown
- 2018-01-03 AU AU2018206564A patent/AU2018206564B2/en active Active
- 2018-01-03 JP JP2019536222A patent/JP7281815B2/ja active Active
- 2018-01-03 CA CA3049226A patent/CA3049226A1/en active Pending
- 2018-01-03 EP EP18736204.1A patent/EP3565539A4/en not_active Withdrawn
- 2018-01-03 CN CN201880005658.8A patent/CN110121337A/zh active Pending
- 2018-01-03 US US16/474,480 patent/US20190336472A1/en not_active Abandoned
- 2018-01-03 BR BR112019013743-2A patent/BR112019013743A2/pt not_active Application Discontinuation
- 2018-01-03 WO PCT/US2018/012261 patent/WO2018129097A1/en not_active Ceased
-
2019
- 2019-07-02 CL CL2019001832A patent/CL2019001832A1/es unknown
- 2019-07-03 IL IL267831A patent/IL267831A/en unknown
- 2019-07-29 CO CONC2019/0008176A patent/CO2019008176A2/es unknown
-
2022
- 2022-06-07 US US17/834,798 patent/US20230293479A1/en not_active Abandoned
-
2023
- 2023-02-10 JP JP2023018922A patent/JP7466238B2/ja active Active
-
2024
- 2024-02-20 AU AU2024201078A patent/AU2024201078A1/en active Pending
- 2024-03-25 JP JP2024047771A patent/JP2024075724A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023071697A5 (https=) | ||
| JP2022031762A5 (https=) | ||
| IL275704B2 (en) | Oral pharmaceutical formulation comprising cannabinoids and poloxamer | |
| JP2019515031A5 (https=) | ||
| JP2020500876A5 (https=) | ||
| RU2020125295A (ru) | Состав с модифицированным высвобождением, содержащий каннабиноид | |
| RU2020125284A (ru) | Фармацевтический препарат | |
| Ribeiro et al. | Modulation of human neutrophils' oxidative burst by flavonoids | |
| PE20190318A1 (es) | Composicion administrable oralmente | |
| RU2007111720A (ru) | Активаторы митохондрий | |
| IL292818A (en) | Microencapsulated cannabinoid preparations | |
| De Almeida | Preclinical and clinical studies of lapachol and beta-lapachone | |
| Sahoo et al. | A brief review: antibacterial activity of quinone derivatives | |
| ATE527995T1 (de) | Medizinische saure cannabinoide | |
| JP2020503357A5 (https=) | ||
| JP2010524912A5 (https=) | ||
| JP2019530751A5 (https=) | ||
| BRPI0821461A8 (pt) | Uso de canabinóides em combinação com um medicamento antipsicótico | |
| US12029719B2 (en) | Compounds comprising cannabinoids and other natural ingredients for alieving premenstrual, menstrual and menopausal symptoms | |
| EP1713467B1 (en) | Compositions and methods of use of a-type procyanidins | |
| ES2346047T3 (es) | Composicion antiarteriosclerosis que comprende fitoeno o fitoflueno. | |
| JP2024514770A (ja) | Ｃｏｖｉｄ－１９の治療及び予防に使用するための化合物 | |
| BR112022021640A2 (pt) | Usos e formulações de canabinoides | |
| JP2025182116A (ja) | 高親油性生理活性物質の放出制御製剤 | |
| US11497727B2 (en) | System and method for making cannabinoid nanoparticle carrier composition |